高雄醫學大學圖書館 |

Controversial statistical issues in clinical trials

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Controversial statistical issues in clinical trials/ Shein-Chung Chow.
Author:	Chow, Shein-Chung,
Published:	Boca Raton :CRC Press, : c2011.,
Description:	1 online resource (xix, 591 p.) :ill. :
基督教聖經之智慧書導讀 :	"Preface In pharmaceutical/clinical development of a test drug or treatment, relevant clinical data are usually collected from subjects with the diseases under study in order to evaluate safety and efficacy of the test drug or treatment under investigation. To provide accurate and reliable assessment, well-controlled clinical trials under valid study design are necessarily conducted. Clinical trial process is a lengthy and costly process, which is necessary to ensure a fair and reliable assessment of the test treatment under investigation. Clinical trial process consists of protocol development, trial conduct, data collection, statistical analysis/interpretation, and reporting. In practice, controversial issues evitably occur regardless the compliance of good statistical practice (GSP) and good clinical practice (GCP). Controversial issues in clinical trials are referred to as debatable issues that are commonly encountered during the conduct of clinical trials. In practice, controversial issues could be raised from, but are not limited to, (1) compromises between theoretical and real/common practices, (2) miscommunication and/or misunderstanding in perception/interpretation among regulatory agencies, clinical scientists, and biostatisticians, and (3) disagreement, inconsistency, miscommunication/misunderstanding, and errors in clinical practice. "--
Subject:	Data Interpretation, Statistical. -
Online resource:	http://www.crcnetbase.com/isbn/9781439849620
ISBN:	9781439849620 (electronic bk.)

Controversial statistical issues in clinical trials
Chow, Shein-Chung,1955-

Controversial statistical issues in clinical trials[electronic resource] /Shein-Chung Chow. - Boca Raton :CRC Press,c2011. - 1 online resource (xix, 591 p.) :ill. - Chapman & Hall/CRC biostatistics series. - Chapman & Hall/CRC biostatistics series..

Includes bibliographical references (p. 553-575) and index.

"Preface In pharmaceutical/clinical development of a test drug or treatment, relevant clinical data are usually collected from subjects with the diseases under study in order to evaluate safety and efficacy of the test drug or treatment under investigation. To provide accurate and reliable assessment, well-controlled clinical trials under valid study design are necessarily conducted. Clinical trial process is a lengthy and costly process, which is necessary to ensure a fair and reliable assessment of the test treatment under investigation. Clinical trial process consists of protocol development, trial conduct, data collection, statistical analysis/interpretation, and reporting. In practice, controversial issues evitably occur regardless the compliance of good statistical practice (GSP) and good clinical practice (GCP). Controversial issues in clinical trials are referred to as debatable issues that are commonly encountered during the conduct of clinical trials. In practice, controversial issues could be raised from, but are not limited to, (1) compromises between theoretical and real/common practices, (2) miscommunication and/or misunderstanding in perception/interpretation among regulatory agencies, clinical scientists, and biostatisticians, and (3) disagreement, inconsistency, miscommunication/misunderstanding, and errors in clinical practice. "--

ISBN: 9781439849620 (electronic bk.)

LCCN: 2011024204Subjects--Topical Terms:

219529
Data Interpretation, Statistical.

LC Class. No.: RM301.27 / .C475 2011

Dewey Class. No.: 615.5072/4

National Library of Medicine Call No.: QV 771

Controversial statistical issues in clinical trials
LDR:02335cam a2200277 a 4500 001 298123
005 20150206143227.0
006 m o d
007 cr |n|---|||||
008 161102s2011 flua ob 001 0 eng
010 $a 2011024204
020 $a 9781439849620 (electronic bk.)
020 $z 9781439849613 (hardback)
035 $a (DNLM)101562559
035 $a 16827822
040 $a DNLM/DLC $c DLC $d DLC
050 0 0 $a RM301.27 $b .C475 2011
060 1 0 $a QV 771
082 0 0 $a 615.5072/4 $2 23
100 1 $2 97000 $a Chow, Shein-Chung, $d 1955- $3 226211
245 1 0 $a Controversial statistical issues in clinical trials $h [electronic resource] / $c Shein-Chung Chow.
260 $a Boca Raton : $b CRC Press, $c c2011.
300 $a 1 online resource (xix, 591 p.) : $b ill.
490 1 $a Chapman & Hall/CRC biostatistics series
504 $a Includes bibliographical references (p. 553-575) and index.
520 $a "Preface In pharmaceutical/clinical development of a test drug or treatment, relevant clinical data are usually collected from subjects with the diseases under study in order to evaluate safety and efficacy of the test drug or treatment under investigation. To provide accurate and reliable assessment, well-controlled clinical trials under valid study design are necessarily conducted. Clinical trial process is a lengthy and costly process, which is necessary to ensure a fair and reliable assessment of the test treatment under investigation. Clinical trial process consists of protocol development, trial conduct, data collection, statistical analysis/interpretation, and reporting. In practice, controversial issues evitably occur regardless the compliance of good statistical practice (GSP) and good clinical practice (GCP). Controversial issues in clinical trials are referred to as debatable issues that are commonly encountered during the conduct of clinical trials. In practice, controversial issues could be raised from, but are not limited to, (1) compromises between theoretical and real/common practices, (2) miscommunication and/or misunderstanding in perception/interpretation among regulatory agencies, clinical scientists, and biostatisticians, and (3) disagreement, inconsistency, miscommunication/misunderstanding, and errors in clinical practice. "-- $c Provided by publisher.
588 $a Description based on print version record.
650 2 2 $2 96060 $a Data Interpretation, Statistical. $3 219529
650 1 2 $2 96060 $a Drug Evaluation, Preclinical. $3 253578
650 1 2 $2 96060 $a Clinical Trials as Topic. $3 244058
650 0 $2 96060 $a Clinical trials. $3 213847
650 0 $2 96060 $a Drug development. $3 232902
650 0 $2 96060 $a Drugs $x Testing. $3 213843
830 0 $a Chapman & Hall/CRC biostatistics series. $3 404943
856 4 0 $u http://www.crcnetbase.com/isbn/9781439849620